Evidence map›Paper›PMID 34667196›Full record

ArticleScientific reports2021

Ameliorative effect of curcumin and zinc oxide nanoparticles on multiple mechanisms in obese rats with induced type 2 diabetes.

Shaymaa Abdulmalek, Asmaa Eldala, Doaa Awad, Mahmoud Balbaa

Open access · goldFull text read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 55 citations in OpenAlex.

  1. Optimized CoQ10 deliveryRSC advances · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Preclinical Safety Assessment ofRecent patents on nanotechnology · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. International journal of molecular sciences · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shaymaa AbdulmalekDepartment of Biochemistry, Faculty of Science, Alexandria University, Alexandria, 21511, Egypt.
Asmaa EldalaDepartment of Biochemistry, Faculty of Science, Alexandria University, Alexandria, 21511, Egypt.
Doaa AwadDepartment of Biochemistry, Faculty of Science, Alexandria University, Alexandria, 21511, Egypt.
Mahmoud BalbaaDepartment of Biochemistry, Faculty of Science, Alexandria University, Alexandria, 21511, Egypt. mahmoud.balbaa@alexu.edu.eg.ORCID 0000-0002-0876-6604
Alexandria University · EGCity of Scientific Research and Technological Applications · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study was carried out to investigate the therapeutic effect of synthesized naturally compounds, curcumin nanoparticles (CurNPs) and metal oxide, zinc oxide nanoparticles (ZnONPs) on a high-fat diet (HFD)/streptozotocin (STZ)-induced hepatic and pancreatic pathophysiology in type 2 diabetes mellitus (T2DM) via measuring AKT pathway and MAPK pathway. T2DM rats were intraperitoneally injected with a low dose of 35 mg/kg STZ after being fed by HFD for 8 weeks. Then the rats have orally received treatments for 6 weeks. HFD/STZ-induced hepatic inflammation, reflected by increased phosphorylation of p38-MAPK pathway's molecules, was significantly decreased after nanoparticle supplementation. In addition, both nanoparticles significantly alleviated the decreased phosphorylation of AKT pathway. Further, administration of ZnONPs, CurNPs, conventional curcumin, and ZnSO

Indexed as

AnimalsAntioxidantsBlood GlucoseCurcuminDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diet, High-FatHypoglycemic AgentsInflammationInsulinInsulin ResistanceLiverMaleMetforminNanoparticlesObesityAntioxidantsBlood GlucoseCurcuminHypoglycemic AgentsInsulinMetforminStreptozocinZinc Oxide

Identifiers

PMID34667196
PMCPMC8526574
OpenAlexW3205178377

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.